Press Releases
CDMO to invest over €3m in GMP facility expansion
Spray drying specialist and capsule filling service provider Micro-Sphere is investing 3.5 million CHF (€3.2 million) into expanding its GMP manufacturing capabilities and processes.
Micro-Sphere will add an additional spray drying line to its facility in Switzerland in response to...
Press Releases
Sterling Pharma Solutions invests $1.5m into US facility expansion
Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, is investing $1.5m into a phased expansion of its US facility in North Carolina.
The investment follows the acquisition of the former US CiVentiChem site earlier this year. Over the...
Press Releases
FlyPharma Europe 2019 – Latest supply chain challenges and industry best practices
For its fifth annual Europe conference, FlyPharma chose Copenhagen as its host city to address the latest supply chain challenges and industry best practices,putting together a global audience of (bio)pharma and logistics professionals.
The two-day conference (22-23 October 2019) aimed...
Press Releases
Natural Extracts Innovated, Transformed and Diversely Laid Out to Embrace the Blue Ocean Market of Big Health
The implementation of the “Healthy China 2030” Planning Outline has ushered in rapid development of China’s big health industry, with the industry scale expected to reach RMB8.78 trillion in 2019 and RMB14.09 trillion in 2023, calculated as per the...
Press Releases
Finalists revealed for CPhI Worldwide’s eagerly anticipated 2019 Awards
CPhI Worldwide announces the finalists for the CPhI Pharma Awards. The shortlist spans 13 different categories across the full spectrum of the pharmaceutical supply chain, including Formulation, Packaging and Lifetime Achievement Awards.
The winners of the 16th CPhI Pharma Awards...
Drug Research
Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells
GammaDelta Therapeutics, a company focussed on harnessing the unique properties of gamma delta T-cells to develop transformational immunotherapies, announced the formation of a spin-out company: Adaptate Biotherapeutics. While GammaDelta Therapeutics’ primary goal is to develop γδ T-cell based cell...
Clinical Trials
Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma
Replimune Group Inc. , a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, announced that the first patient has been enrolled in its registration-directed, randomized, controlled Phase 2 clinical trial of RP1 in combination with Regeneron...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read